Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

NCT02954874 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02954874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02954874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 18, 2017
Completion date
August 27, 2027
Enrollment
1,195 (actual)
Sites
919

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma in situ, invasive breast carcinoma, stage i breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iii breast cancer ajcc v7, triple-negative breast carcinoma